Rhelion Life Sciences Corp., a company operating within the capital markets sector, has recently made significant strides in the burgeoning field of psychedelic medicine. The company, listed on the Canadian National Stock Exchange, has seen its share price fluctuate over the past year, with a close price of CAD 0.03 as of August 6, 2026. Despite a market capitalization of CAD 17,871,836, the company’s price-to-earnings ratio stands at -3.88, reflecting its current financial dynamics.
In a notable development, Rhelion Life Sciences Corp. announced that its wholly-owned subsidiary, Filament Health, has been granted a new Canadian patent. This patent covers the extraction, purification, stabilization, and composition of its natural psilocybin drug candidate, PEX010. This advancement is a significant milestone for Rhelion, as it expands the company’s extensive natural-psilocybin patent portfolio, which now includes 78 issued patents across 13 families in multiple jurisdictions.
PEX010, a GMP-manufactured botanical product, is supplied in standardized doses and is currently supporting over 80 research and compassionate-access studies worldwide. This positions Rhelion at the forefront of the legal psychedelic sector, where it continues to make substantial contributions to research and development.
Earlier this year, Rhelion completed the acquisition of Filament Health, a strategic move that integrated the subsidiary’s clinical infrastructure and intellectual property into Rhelion’s operations. This acquisition not only bolstered Rhelion’s capabilities but also reinforced its commitment to advancing the field of psychedelic medicine.
The new patent is a testament to Rhelion’s innovative approach and dedication to providing high-quality, consistent, and sustainable products. By leveraging cutting-edge technology and operational efficiency, Rhelion aims to solidify its position as a leader in the global cannabis and psychedelic industries. This development underscores the company’s ongoing efforts to support research and supply activities, ultimately contributing to the broader acceptance and understanding of psychedelic medicine.
